Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Ligand Pharmaceuticals (LGND) over the last 14 years, with Sep 2025 value amounting to $219,000.

  • Ligand Pharmaceuticals' Gains from Investment Securities rose 75.20% to $219,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 214.24%. This contributed to the annual value of $5.1 million for FY2024, which is 12.95% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Gains from Investment Securities of $219,000 as of Q3 2025, which was up 51.03% from $145,000 recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Gains from Investment Securities peaked at $11.0 million during Q3 2023, and registered a low of -$10.7 million during Q4 2023.
  • In the last 3 years, Ligand Pharmaceuticals' Gains from Investment Securities had a median value of $1.1 million in 2024 and averaged $1.9 million.
  • Examining YoY changes over the last 5 years, Ligand Pharmaceuticals' Gains from Investment Securities showed a top increase of 11,408.33% in 2023 and a maximum decrease of 581.88% in 2023.
  • Ligand Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $3.3 million in 2021, then crashed by 98.17% to $2.2 million in 2022, then crashed by 581.88% to -$10.7 million in 2023, then surged by 118.10% to $1.9 million in 2024, then skyrocketed by 75.20% to $219,000 in 2025.
  • Its last three reported values are $219,000 in Q3 2025, $145,000 for Q2 2025, and $8.9 million during Q1 2025.